SURMOUNT
The study will assess the effect of tirzepatide at the maximum tolerated dose (10 mg or 15 mg QW) compared with placebo in people living with obesity
- Stadium
- followup
- Middel
- Tirzepatide
- Populatie
- ASCVD
- Fase
- III
- First Patient In
- 31 januari 2023
- Last Patient In
- 5 februari 2024
- Last Patient Last Visit
- 30 juni 2029
National Lead
dr. A.F.M. Kuijper
Cardioloog
Studiedirecteur
drs. M.J. Asselman
Cardioloog
Contact Kantoor
